Beam Therapeutics Inc. (BEAM)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 02:33PM EDT. Market open.
| Previous close | 23.13 |
| Open | 23.34 |
| Bid | 22.79 x 100 |
| Ask | 22.96 x 100 |
| Day's range | 22.75 - 23.71 |
| 52-week range | 16.95 - 49.50 |
| Volume | |
| Avg. volume | 1,530,258 |
| Market cap | 1.883B |
| Beta (5Y monthly) | 1.77 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.72 |
| Earnings date | 08 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 50.00 |
ZacksUltragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates
Ultragenyx (RARE) delivered earnings and revenue surprises of -18.02% and 4.86%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
ZacksBeam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Beam Therapeutics (BEAM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Simply Wall St.Beam Therapeutics (NASDAQ:BEAM) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
© 2024 Yahoo. All rights reserved.